Get the Stockscreener App
40.94
0.05%
0.04
After Hours:
40.89
-0.05
-0.12%
Apellis Pharmaceuticals Inc stock is traded at $40.94, with a volume of 4.11M.
It is up +0.05% in the last 24 hours and up +137.77% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
See More
Previous Close:
$40.90
Open:
$40.88
24h Volume:
4.11M
Relative Volume:
0.82
Market Cap:
$5.23B
Revenue:
$1.00B
Net Income/Loss:
$22.39M
P/E Ratio:
331.50
EPS:
0.1235
Net Cash Flow:
$45.01M
1W Performance:
+0.20%
1M Performance:
+137.77%
6M Performance:
+51.16%
1Y Performance:
+124.84%
1-Day Range:
$40.86
$40.94
1-Week Range:
$40.78
$40.95
52-Week Range:
$16.10
$40.95
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
40.94 | 5.23B | 1.00B | 22.39M | 45.01M | 0.1235 |
VRTX
Vertex Pharmaceuticals Inc
|
439.18 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.41 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
834.45 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.94 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
318.07 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Initiated | Roth Capital | Buy |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Jan-21-26 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-06-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-15-25 | Initiated | Wells Fargo | Overweight |
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Apellis Pharmaceuticals (APLS) Tops Overbought Healthcare Stocks List - GuruFocus
Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on (XLV:NYSEARCA) - Seeking Alpha
Biogen raised to overweight at Piper Sandler on Apellis buyout - MSN
Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy Alliance - Yahoo Finance
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
Technical Reactions to APLS Trends in Macro Strategies - Stock Traders Daily
Biogen’s Apellis Deal Reshapes Growth Story And Pipeline Priorities - simplywall.st
Wells Fargo downgrades Apellis Pharmaceuticals (APLS) - MSN
Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates - Eastern Progress
APLS Downgraded by Wells Fargo -- Price Target Raised to $41 - GuruFocus
Wells Fargo Downgrades Apellis Pharmaceuticals(APLS.US) to Hold Rating, Raises Target Price to $41 - Moomoo
Apellis (APLS) Receives Downgrade from Wells Fargo with New Pric - GuruFocus
Apellis Pharmaceuticals' (APLS) Equal Weight Rating Reiterated at Wells Fargo & Company - MarketBeat
Apellis Pharmaceuticals Inc (NASDAQ:APLS) Emerges as a Growth Stock with Bullish Technical Breakout Potential - ChartMill
Apellis Pharmaceuticals stock hits 52-week high at 40.87 USD By Investing.com - Investing.com Australia
Mizuho reiterates Apellis stock rating citing M&A process details - Investing.com
Mizuho reiterates Apellis stock rating citing M&A process details By Investing.com - Investing.com Canada
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
Apellis Pharmaceuticals stock hits 52-week high at 40.87 USD - Investing.com
M&A Class Action Firm Investigating Multiple Mergers - National Today
Biogen stock upgraded at Piper Sandler (BIIB:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals | SC TO-T: Third party tender offer statement - Moomoo
Apellis (APLS) board recommends $41 cash takeover by Biogen with up to $4 CVR - Stock Titan
Biogen (NASDAQ: APLS) bids $41 per share plus up to $4 CVR for Apellis - Stock Titan
Wellington Management Group LLP Significantly Reduces Stake in Apellis Pharmaceuticals Inc - GuruFocus
Support Test: Can Apellis Pharmaceuticals Inc stock outperform in a bear marketMarket Weekly Review & Precise Buy Zone Tips - baoquankhu1.vn
Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week HighShould You Buy? - MarketBeat
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Valuation Update: Does Apellis Pharmaceuticals Inc stock have upside surprise potential - baoquankhu1.vn
Biogen lands two fast-growing drugs in blockbuster Apellis deal - MSN
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - Finviz
JPMorgan Chase & Co. Sells 181,285 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Hold" by Analysts - MarketBeat
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Wealth Enhancement Advisory Services LLC - MarketBeat
US Market Recap: Will Apellis Pharmaceuticals Inc benefit from geopolitical trendsQuarterly Portfolio Report & High Return Trade Guides - baoquankhu1.vn
Apellis (APLS) director shifts 5,750 trust shares to spouse account - Stock Titan
Apellis Stock More Than Doubles on Biogen News. Here’s What to Know. - Barron's
Trading the Move, Not the Narrative: (APLS) Edition - Stock Traders Daily
Biogen’s Apellis Deal And High Dose SPINRAZA Shift Growth Outlook - Sahm
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? - Sahm
Apellis Pharmaceuticals Stock Rockets 140% With 6-Day Winning Streak - Trefis
6-Day Rally Sends Apellis Pharmaceuticals Stock Up 140% - Trefis
Apellis Pharmaceuticals stock reaches 52-week high at $40.71 By Investing.com - Investing.com Australia
Biogen (NASDAQ: APLS) readies tender offer for Apellis under March 31, 2026 deal - Stock Titan
Apellis Pharmaceuticals stock reaches 52-week high at $40.71 - Investing.com
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):